The U.S. Food and Drug Administration (FDA) has granted approval for daraxonrasib, a new medication designed to treat pancreatic cancer. Marketed as Rasonque and produced by Revolution Medicines, the drug is being hailed as a significant advancement for a condition that remains one of the most lethal and challenging to manage.
Clinical testing involving 500 participants demonstrated that the daily oral treatment extended average survival to 13.2 months, a substantial increase compared to the 6.6 months observed in patients receiving standard chemotherapy. The drug functions by targeting and deactivating the mutated KRAS gene, a driver of tumor growth present in over 90% of pancreatic cancer cases.
The FDA expedited the approval process, finalizing the decision six months before the regulatory deadline. Angelo de Claro, director of the agency's Oncology Center of Excellence, noted that the drug was fast-tracked because it demonstrated "unprecedented results in an area of high unmet need." The agency previously designated the treatment as a "Breakthrough Therapy" in 2025.
While the treatment is associated with side effects such as nausea, fatigue, diarrhea, vomiting, and rashes, the trial data indicated that severe side effects occurred in 44% of those taking daraxonrasib, compared to 57.5% of those undergoing chemotherapy. Former U.S. Senator Ben Sasse, who is currently undergoing treatment for Stage 4 pancreatic cancer, has reported that the drug has contributed to the shrinkage of his tumors.
Pancreatic cancer is frequently diagnosed at advanced stages, with the American Cancer Society reporting that more than half of patients succumb to the disease within three months of diagnosis. Approximately 67,000 individuals are diagnosed with the cancer annually in the United States.
Source: BBC News
No comments yet. Be the first to share your thoughts.